Provided by Tiger Fintech (Singapore) Pte. Ltd.

Solid Biosciences

3.21
-0.0900-2.73%
Post-market: 3.230.0200+0.62%19:57 EDT
Volume:868.95K
Turnover:2.78M
Market Cap:248.82M
PE:-1.05
High:3.27
Open:3.25
Low:3.10
Close:3.30
Loading ...

Solid Biosciences 35.74M share Spot Secondary priced at $4.03

TIPRANKS
·
18 Feb

BRIEF-Solid Biosciences Announces Pricing Of Underwritten Offering

Reuters
·
18 Feb

Solid Biosciences Inc - Prices Offering of 35.7 Mln Shares at $4.03/Share

THOMSON REUTERS
·
18 Feb

Solid Biosciences Announces Pricing of Underwritten Offering

THOMSON REUTERS
·
18 Feb

Solid Biosciences Announces Pricing of Underwritten Offering

GlobeNewswire
·
18 Feb

BRIEF-Solid Biosciences Reports Positive Initial Clinical Data from SGT-003

Reuters
·
18 Feb

Solid Biosciences Inc - Average Microdystrophin Expression of 110% Observed in Phase 1/2 Trial of Sgt-003

THOMSON REUTERS
·
18 Feb

Solid Biosciences - Plans to Request FDA Meeting for Accelerated Approval Pathway in Mid-2025 for Sgt-003

THOMSON REUTERS
·
18 Feb

Solid Biosciences Inc: Sgt-003 Has Been Well-Tolerated With No Serious Adverse Events Observed

THOMSON REUTERS
·
18 Feb

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

GlobeNewswire
·
18 Feb

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

TipRanks
·
09 Feb

Positive Outlook for Solid Biosciences: Anticipated Trial Data and Gene Therapy Platform Drive Buy Rating

TIPRANKS
·
05 Feb

Solid Biosciences reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Feb

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Feb

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Feb

Solid Biosciences Gets Fast Track Designation for Potential Friedreich's Ataxia Treatment

MT Newswires Live
·
22 Jan

Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation

Dow Jones
·
21 Jan

Solid Biosciences receives FDA Fast Track Designation for SGT-212

TIPRANKS
·
21 Jan

Solid Biosciences Receives FDA Fast Track Designation for Sgt-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

THOMSON REUTERS
·
21 Jan

Solid Biosciences Inc - Sgt-212 Dosing Expected to Initiate in Second Half of 2025

THOMSON REUTERS
·
21 Jan